Black Friday Get Elite for just $149.00 Claim Now

BlossomHill Therapeutics, Inc.

Contributing Author

Recent Articles by BlossomHill Therapeutics, Inc.

Nov-12	BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights BLSM -7.57% BLSM -5.53% GlobeNewswire
Nov-09	BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC BLSM +7.11% GlobeNewswire
Nov-04	BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting BLSM GlobeNewswire
Nov-03	BlossomHill Therapeutics to Present at Guggenheim's 3rd Annual Healthcare Innovations Conference BLSM GlobeNewswire
Oct-22	BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer BLSM GlobeNewswire
Sep-28	BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer BLSM +8.05% GlobeNewswire
Sep-18	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results BLSM GlobeNewswire
Sep-15	BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer BLSM GlobeNewswire
Sep-03	BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference BLSM GlobeNewswire
Sep-01	BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer BLSM GlobeNewswire
Aug-18	BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC BLSM GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)